Technology | Clinical Decision Support | February 14, 2018

FDA Clears First AI-Powered Clinical Decision Support Software for Stroke

Viz.AI Contact application uses artificial intelligence algorithm to analyze CT images for stroke indicators; approval paves way for future computer-aided triage software devices

FDA Clears First AI-Powered Clinical Decision Support Software for Stroke

February 14, 2018 — The U.S. Food and Drug Administration (FDA) announced marketing clearance for Viz.AI’s Contact application, the first artificial intelligence (AI)-based clinical decision support (CDS) solution cleared for sale in the U.S. Viz.AI Contact is designed to analyze computed tomography (CT) results that may notify providers of a potential stroke in their patients.

A stroke occurs if the flow of oxygen-rich blood to a portion of the brain is blocked, also known as an occlusion. According to the Centers for Disease Control and Prevention, stroke is the fifth leading cause of death in the U.S. and is a major cause of serious disability for adults. About 795,000 people in the U.S. have a stroke each year.

“Strokes can cause serious and irreversible damage to patients. The software device could benefit patients by notifying a specialist earlier thereby decreasing the time to treatment. Faster treatment may lessen the extent or progression of a stroke,” said Robert Ochs, Ph.D., acting deputy director for radiological health, Office of In Vitro Diagnostics and Radiological Health in the FDA’s Center for Devices and Radiological Health.

The Viz.AI Contact application is a computer-aided triage software that uses an artificial intelligence algorithm to analyze images for indicators associated with a stroke. These types of algorithms can assist providers in identifying the most appropriate treatment plan for a patient’s disease or condition. The FDA is currently creating a regulatory framework for these products that encourages developers to create, adapt and expand the functionalities of their software to aid providers in diagnosing and treating diseases and conditions.

The Viz.AI Contact application is designed to analyze CT images of the brain and send a text notification to a neurovascular specialist if a suspected large vessel occlusion (LVO) has been identified. The algorithm will automatically notify the specialist during the same time the first-line provider is conducting a standard review of the images, potentially involving the specialist sooner than the usual standard of care in which patients wait for a radiologist to review CT images and notify a neurovascular specialist. The notification can be sent to a mobile device, such as a smartphone or tablet, but the specialist still needs to review the images on a clinical workstation.

The Viz.AI Contact application is intended to be used by neurovascular specialists, such as vascular neurologists, neuro-interventional specialists or other professionals with similar training. The application is limited to analysis of imaging data and should not be used as a replacement of a full patient evaluation or solely relied upon to make or confirm a diagnosis.

The company submitted a retrospective study of 300 CT images that assessed the independent performance of the image analysis algorithm and notification functionality of the Viz.AI Contact application against the performance of two trained neuro-radiologists for the detection of large vessel blockages in the brain. Real-world evidence was used with a clinical study to demonstrate that the application could notify a neurovascular specialist sooner in cases where a blockage was suspected. The Viz.ai LVO Stroke Platform obtained an AUC of 0.91, identifying LVOs and alerting the relevant specialist with 90 percent sensitivity and specificity, and a median scan to notification time of under 6 minutes. In over 95 percent of cases, the automatic notifications demonstrated faster notification of the specialist, saving between 6 and 206 minutes, with an average time saving of 52 minutes.

The Viz.AI Contact application was reviewed through the De Novo premarket review pathway, a regulatory pathway for some new types of medical devices that are low to moderate risk and have no legally marketed predicate device to base a determination of substantial equivalence. This action also creates a new regulatory classification, which means that subsequent computer-aided triage software devices with the same medical imaging intended use may go through the FDA’s premarket 510(k) notification process, whereby devices can obtain marketing authorization by demonstrating substantial equivalence to a predicate device.

For more information: www.viz.ai

Related Artificial Intelligence Content

Technology Report: Artificial Intelligence 2017

Why AI By Any Name Is Sweet For Radiology

VIDEO: Examples of How Artificial Intelligence Will Improve Medical Imaging

VIDEO: Deep Learning is Key Technology Trend at RSNA 2017

Machine Learning Concerns Discussed at RSNA/AAPM Symposium

 

Related Content

NewYork-Presbyterian Hospital Partners With Philips for Health IT and Clinical Informatics
News | Enterprise Imaging | January 16, 2019
Philips announced that NewYork-Presbyterian Hospital has chosen to implement the company’s IntelliSpace Enterprise...
Artificial Intelligence Used in Clinical Practice to Measure Breast Density
News | Artificial Intelligence | January 15, 2019
An artificial intelligence (AI) algorithm measures breast density at the level of an experienced mammographer,...
Sponsored Content | Videos | Artificial Intelligence | January 15, 2019
ITN Contributing Editor Greg Freiherr offers an overview of...
Machine Learning Uncovers New Insights Into Human Brain Through fMRI
News | Neuro Imaging | January 11, 2019
An interdisciplinary research team led by scientists from the National University of Singapore (NUS) has successfully...
Videos | Interventional Radiology | January 11, 2019
Julius Chapiro, M.D., research faculty member and an...
AI Approach Outperformed Human Experts in Identifying Cervical Precancer
News | Digital Pathology | January 10, 2019
January 10, 2019 — A research team led by investigators from the National Institutes of Health and Global Good has de
Artificial intelligence, also called deep learning and machine learning, was the hottest topic at the 2018 Radiological Society of North America (RSNA)) meeting.

Artificial intelligence was the hottest topic at the 2018 Radiological Society of North America (RSNA)) meeting, which included a large area with its own presentation therater set asside for AI vendors.

Feature | Artificial Intelligence | January 10, 2019 | Dave Fornell, Editor
Hands down, the hottest topic in radiology the past two years has been the implementation of...
Pacific Northwest VA Network Selects Carestream as Enterprise PACS Supplier
News | PACS | January 08, 2019
Carestream has been awarded a multimillion-dollar healthcare information technology (IT) contract for Veterans Affairs...
Artificial Intelligence Pinpoints Nine Different Abnormalities in Head Scans

A brain scan (left) showing an intraparenchymal hemorrhage in left frontal region and a scan (right) of a subarachnoid hemorrhage in the left parietal region. Both conditions were accurately detected by the Qure.ai tool. Image courtesy of Nature Medicine.

News | Artificial Intelligence | January 07, 2019
The rise in the use of computed tomography (CT) scans in U.S. emergency rooms has been a well-documented trend1 in...